Meiji Holdings Co Ltd
TSE:2269
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2 912
3 597
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Meiji Holdings Co Ltd
Meiji Holdings Co., Ltd. has long been a staple in the world of Japanese consumer goods, specifically in the food and pharmaceutical sectors. Established in 2009 as a result of merging Meiji Seika Kaisha, Ltd. and Meiji Dairies Corporation, the company stands as a testament to the power of strategic consolidation, leveraging over a century of expertise from its predecessors. The company's robust product portfolio spans a diverse array of offerings, including dairy products like yogurts and milk, confectioneries like chocolate and candy, as well as nutrition bars and supplements. This triumvirate of product lines allows Meiji Holdings to position itself in both the everyday consumer market and in specialized health-centric industries, exploiting economies of scale and extensive distribution networks that reach far beyond the Japanese archipelago.
In the pharmaceutical arena, Meiji Holdings operates under its subsidiary, Meiji Seika Pharma, focusing predominantly on antibacterial drugs, central nervous system treatments, and veterinary products. By integrating research and development with a comprehensive marketing strategy, the company capitalizes on global health trends and regional disease challenges, expanding in markets that emphasize health and dietary improvements. Financially, Meiji Holdings generates revenue by producing goods that tap into both traditional consumer desires and modern nutritional trends. It makes money by introducing high-margin pharmaceutical innovations alongside its well-established consumer brands, thus benefiting from both everyday sales and solutions aimed at pressing global health needs. Together, these strategic components make Meiji Holdings an agile player in a competitive global market, combining heritage with innovation.
Meiji Holdings Co., Ltd. has long been a staple in the world of Japanese consumer goods, specifically in the food and pharmaceutical sectors. Established in 2009 as a result of merging Meiji Seika Kaisha, Ltd. and Meiji Dairies Corporation, the company stands as a testament to the power of strategic consolidation, leveraging over a century of expertise from its predecessors. The company's robust product portfolio spans a diverse array of offerings, including dairy products like yogurts and milk, confectioneries like chocolate and candy, as well as nutrition bars and supplements. This triumvirate of product lines allows Meiji Holdings to position itself in both the everyday consumer market and in specialized health-centric industries, exploiting economies of scale and extensive distribution networks that reach far beyond the Japanese archipelago.
In the pharmaceutical arena, Meiji Holdings operates under its subsidiary, Meiji Seika Pharma, focusing predominantly on antibacterial drugs, central nervous system treatments, and veterinary products. By integrating research and development with a comprehensive marketing strategy, the company capitalizes on global health trends and regional disease challenges, expanding in markets that emphasize health and dietary improvements. Financially, Meiji Holdings generates revenue by producing goods that tap into both traditional consumer desires and modern nutritional trends. It makes money by introducing high-margin pharmaceutical innovations alongside its well-established consumer brands, thus benefiting from both everyday sales and solutions aimed at pressing global health needs. Together, these strategic components make Meiji Holdings an agile player in a competitive global market, combining heritage with innovation.
Operating Profit Beat: First-half operating profit reached JPY 40.9 billion, beating the company plan of JPY 39.5 billion, mainly on strong Pharmaceuticals performance.
Net Sales Softness: First-half consolidated net sales were JPY 574.8 billion, up 1.0% year-on-year but below initial plan, prompting a slight downward revision to full-year sales guidance.
Net Profit Decline: Net profit for the first half was JPY 21.4 billion, down 20.1% year-on-year, missing plan by JPY 1 billion due to tax and minority interest impacts.
Unchanged Profit Guidance: Despite lower sales outlook, full-year operating profit and net income guidance remain unchanged.
Cost & Pricing Actions: Price increases and cost management are helping offset higher raw material and logistics costs, with further structural reforms underway.
Segment Highlights: Food profit is growing despite mixed product performance; Pharmaceuticals saw strong vaccine results, but major antibiotics lagged.
China Strategy: The company is reviewing its overseas food strategy, with a focus on improving performance and allocating resources to stronger confectionery businesses.